222 related articles for article (PubMed ID: 16230005)
21. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
[TBL] [Abstract][Full Text] [Related]
22. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
[TBL] [Abstract][Full Text] [Related]
23. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
24. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.
Young OE; Renshaw L; Macaskill EJ; White S; Faratian D; Thomas JS; Dixon JM
Eur J Cancer; 2008 Feb; 44(3):391-9. PubMed ID: 18083023
[TBL] [Abstract][Full Text] [Related]
25. Fulvestrant (Faslodex) -- how to make a good drug better.
Robertson JF
Oncologist; 2007 Jul; 12(7):774-84. PubMed ID: 17673609
[TBL] [Abstract][Full Text] [Related]
26. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
[TBL] [Abstract][Full Text] [Related]
27. Fulvestrant in postmenopausal women with advanced breast cancer.
Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
[TBL] [Abstract][Full Text] [Related]
28. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Howell A; Robertson JF; Abram P; Lichinitser MR; Elledge R; Bajetta E; Watanabe T; Morris C; Webster A; Dimery I; Osborne CK
J Clin Oncol; 2004 May; 22(9):1605-13. PubMed ID: 15117982
[TBL] [Abstract][Full Text] [Related]
29. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
30. A new estrogen receptor antagonist--an overview of available data.
Jones SE
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
[TBL] [Abstract][Full Text] [Related]
31. Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
Robertson JFR; Steger GG; Neven P; Barni S; Gieseking F; Nolè F; Pritchard KI; O'Malley FP; Simon SD; Kaufman B; Petruzelka L
Ann Oncol; 2010 Jun; 21(6):1246-1253. PubMed ID: 19875750
[TBL] [Abstract][Full Text] [Related]
32. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Oakman C; Moretti E; Santarpia L; Di Leo A
Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
[TBL] [Abstract][Full Text] [Related]
33. Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
Lynn J
Eur J Oncol Nurs; 2004; 8 Suppl 2():S83-8. PubMed ID: 15590319
[TBL] [Abstract][Full Text] [Related]
34. Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
Wang J; Jain S; Coombes CR; Palmieri C
Breast J; 2009; 15(3):247-53. PubMed ID: 19645779
[TBL] [Abstract][Full Text] [Related]
35. The future of fulvestrant ("Faslodex").
Howell A
Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
[TBL] [Abstract][Full Text] [Related]
36. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
[TBL] [Abstract][Full Text] [Related]
37. Pure oestrogen antagonists for the treatment of advanced breast cancer.
Howell A
Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
[TBL] [Abstract][Full Text] [Related]
38. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Scott SM; Brown M; Come SE
Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
[TBL] [Abstract][Full Text] [Related]
39. Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients.
Warm M; Kates R; Overkamp F; Thomas A; Harbeck N
Breast Cancer Res Treat; 2011 Jan; 125(1):127-36. PubMed ID: 20960229
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of fulvestrant in clinical practice: use of an electronic data registry.
Lower EE; Esparaz BT; Garnett SA; Wade JL
Clin Breast Cancer; 2007 Apr; 7(7):565-9. PubMed ID: 17509166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
